ASS1 and acute myeloid leukemia: Clinical trials are ongoing (NCT01910012 and NCT02875093) in this regard but have thus far demonstrated the capacity of ADI-PEG20 to induce complete remissions or the control of the disease in only some patients suggesting that ASS deficiency is not a sufficient condition for response to ADI-PEG20 monotherapy in AML (76).